MAXCYTE INC

For the period ended Dec 31, 2023. Filed Mar 12, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 12, 2024

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(in thousands)


· Year Ended December 31, ·
· · 2023 · 2022
Cash flows from operating activities: · ·
Net loss	$(37,923)	$(23,571)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,171	2,698
Non-cash lease expense	395	767
Net book value of consigned equipment sold	94	76
Loss on disposal of fixed assets	30	139
Stock-based compensation	13,979	11,752
Bad debt expense	171	—
Change in excess/obsolete inventory reserve	697	—
Amortization of discounts on investments	(7,120)	(2,667)

Changes in operating assets and liabilities:
Accounts receivable	5,226	(4,569)
Accounts receivable - TIA	1,912	(1,912)
Inventory	(4,534)	(3,493)
Prepaid expense and other current assets	(641)	320
Other assets	421	(492)
Accounts payable, accrued expenses and other	3,252	(150)
Operating lease liability	(133)	5,482
Deferred revenue	(1,644)	(34)
Other liabilities	(39)	871
Net cash used in operating activities	(21,686)	(14,783)

Cash flows from investing activities:
Purchases of investments	(255,095)	(290,942)
Maturities of investments	313,770	284,596
Purchases of property and equipment	(3,700)	(18,477)
Proceeds from sale of equipment	9	—
Net cash provided by (used in) investing activities	54,984	(24,823)

Cash flows from financing activities:
Proceeds from exercise of stock options	1,874	2,888
Proceeds from issuance of common stock under employee stock purchase plan	269	—
Net cash provided by financing activities	2,143	2,888
Net increase (decrease) in cash and cash equivalents	35,441	(36,718)
Cash and cash equivalents, beginning of year	11,065	47,783
Cash and cash equivalents, end of year	$46,506	$11,065

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses	$566	$363
Lease liability reduction due to operating lease modification and early termination	$—	$540
Right-of-use assets obtained in exchange for lease liabilities	$1,782	$5,476

MaxCyte, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.